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The biomolecule corona of lipid nanoparticles
contains circulating cell-free DNA†
Lois Gardner, ab Jessica Warrington, a Jane Rogan,c Dominic G. Rothwell, b
Ged Brady,b Caroline Dive,b Kostas Kostarelos *ade and
Marilena Hadjidemetriou *a
The spontaneous adsorption of biomolecules onto the surface of
nanoparticles (NPs) in complex physiological biofluids has been widely
investigated over the last decade. Characterisation of the protein
composition of the ‘biomolecule corona’ has dominated research
efforts, whereas other classes of biomolecules, such as nucleic acids,
have received no interest. Scarce, speculative statements exist in the
literature about the presence of nucleic acids in the biomolecule corona,
with no previous studies attempting to describe the contribution of
genomic content to the blood-derived NP corona. Herein, we provide
the first experimental evidence of the interaction of circulating cell-free
DNA (cfDNA) with lipid-based NPs upon their incubation with human
plasma samples, obtained from healthy volunteers and ovarian carci-
noma patients. Our results also demonstrate an increased amount of
detectable cfDNA in patients with cancer. Proteomic analysis of the
same biomolecule coronas revealed the presence of histone proteins,
suggesting an indirect, nucleosome-mediated NP–cfDNA interaction.
The finding of cfDNA as part of the NP corona, offers a previously
unreported new scope regarding the chemical composition of the
‘biomolecule corona’ and opens up new possibilities for the potential
exploitation of the biomolecule corona for the enrichment and analysis
of blood-circulating nucleic acids.
Introduction
Over the last decade, biomedical applications of nanoparticles
(NPs) have been challenged due to the spontaneous adsorption
of biomolecules onto their surface upon incubation with
complex biofluids, known as the ‘protein’ or ‘biomolecule
corona’.1,2 The bio-nanotechnology field has since invested
considerable resources investigating the corona composition
in an attempt to prevent NP–protein interactions and con-
sequently limit opsonisation-mediated clearance from blood
and ‘masking’ of surface ligands.3–6 Protein corona formation
is now a widely accepted phenomenon and has been documented
for a wide range of NPs, including lipid-, metal-, polymer- and
carbon-based nanomaterials, with their composition and surface
chemistry altering the specific classes of proteins adsorbed.7
More recently, attempts have been made to purposefully
manipulate the NP corona to modify the function of NPs4,8 and
this approach has since been exploited as an application in its
own right.9–12 For example, altering the surface properties of
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The aim of this study was to interrogate experimentally the fundamental
question whether circulating cell-free DNA (cfDNA) exists in the bio-
molecule corona that spontaneously forms around nanoparticles upon
incubation with complex biological fluids. Despite recent advances in the
characterisation of the protein content of the biomolecule corona, to date
there has been no experimental evidence of the spontaneous interaction
between cfDNA and plasma-incubated nanoparticles. To test this hypo-
thesis and analyse such genomic content in the nanoparticle biomolecule
corona, we incubated clinically-used liposomes with human plasma
samples, retrieved their coronas and subsequently quantified the total
corona cfDNA content using two different real-time quantitative PCR
(qPCR) assays. Our data revealed the presence of cfDNA in the liposomal
biomolecule corona upon their incubation with human plasma samples
obtained from healthy donors and ovarian carcinoma patients. More
interestingly, an increased amount of corona cfDNA was detected in
cancer patients. Finally, proteomic analysis of the same biomolecule
coronas revealed the presence of histone proteins, suggesting an
indirect, nucleosome-mediated NP–cfDNA interaction. The revelation of
cfDNA as a component of the nanoparticle corona, opens up new
possibilities for the potential exploitation of the biomolecule corona for
the enrichment and analysis of blood-circulating nucleic acids and the
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NPs not only alters the corona composition but has also been
shown to control the loading and release of drugs and inter-
action with target molecules.13,14 Manipulating the corona by
engineering the surface chemistry of NPs can therefore enhance
their biological efficacy.4,6 In an alternative proposition, our
laboratory has illustrated the potential exploitation of protein
corona as a proteomic biomarker discovery platform that enables
a higher-definition, in-depth analysis of the blood proteome and
the enrichment of low abundant disease-specific molecules.9–12
Despite the comprehensive characterisation of the blood-
derived NP protein corona in mice and humans (both ex vivo
and in vivo),10,13,15–19 little attention has been placed on other
types of biomolecules that may constitute the biomolecule
corona. Growing evidence suggests that lipids and metabolites
also interact with the surface of NPs.20–29 For example, a
comprehensive metabolomic analysis at the nano-bio interface
between mineralo-organic NPs and human biofluids (serum,
plasma, saliva, and urine) revealed a range of metabolites
including amino acids, sugars, amides, fatty acids and glycero-
phospholipids.24 More recently, the formation of a ‘metabolite’
corona has been shown using different NPs including, copper
oxide, titanium dioxide, zinc oxide, zirconium dioxide, carbon25
and amino-functionalised polystyrene NPs.26 The lipid and meta-
bolite composition of the liposomal corona has also been
characterised in human plasma, revealing a complex lipid and
metabolite profile.27 Notably, a recent study investigating the
metabolite ‘small molecule’ corona formed around a range of
nanomaterials revealed the presence of charged metabolites
including amino acids and nucleosides.22 These studies highlight
the diverse and complex composition of the biomolecule corona.
Scarce speculative statements exist in the literature referencing
the presence of nucleic acids in the biomolecule corona.30–32
However, the genomic content of the blood-derived NP corona
has never been investigated and there is no experimental evidence
to support that the NP corona contains cell-free DNA (cfDNA).
This could be partially due to the experimental challenges in
identifying minute levels of blood-circulating nucleic acids on the
NPs surfaces. The very few studies that have tried to investigate
any role that nucleic acids may play in the biomolecule corona,
focused on miRNAs using rat urine samples,33 or attempted to
understand the interaction of NPs with added synthetic DNA
fragments in solution.31,34 NPs have also been extensively used
as biosensors or as nano-carriers to deliver nucleic acids, with
positively charged lipid-, polymeric-, gold- and carbon-based
(among many other) NPs used to deliver electrostatically-
complexed nucleic acids for therapeutic applications.34–42
In an alternative approach, Liang et al., intravenously adminis-
tered cationic polymeric NPs to complex cfDNA in vivo to
alleviate the symptoms of inflammation in rheumatoid arthritis
(RA).53 Despite these approaches of electrostatic complexation
of nucleic acids with cationic NPs, the spontaneous association
of blood-derived cfDNA molecules with NPs has largely been
ignored, presumably because it was thought that other blood
components competitively self-assemble into layers around
NPs. It is also worth mentioning that the majority of
NP-based colorimetric cfDNA biosensors require the purification
of cfDNA from plasma samples prior to the incubation with
NPs.43,44
The aim of the present study was to offer experimental
evidence on the fundamental question as to whether cfDNA
exists in the biomolecule corona formed around NPs in human
plasma. In order to investigate this, we incubated clinically-
used types of liposomes with plasma samples, retrieved the
corona-coated liposomes, and subsequently quantified the total
corona cfDNA content using two different real-time quantitative
PCR (qPCR) assays. Our data confirmed the presence of cfDNA
molecules in the biomolecule corona. In addition, analysis of
the liposome corona formed in plasma samples obtained from
ovarian carcinoma patients revealed higher total cfDNA content
compared to healthy controls, suggesting a disease-specific
biomolecule corona. Finally, correlation with the proteomic
analysis of the same liposomal coronas revealed nucleosome-
derived histone proteins, which suggested an indirect, protein-
mediated cfDNA interaction with NPs.
Results
Plasma incubation and biomolecule corona formation
To evaluate the cfDNA content of the biomolecule corona,
human plasma samples obtained from healthy volunteers were
incubated (37 1C, 10 minutes, 250 rpm) with PEGylated lipo-
somes (HSPC:Chol:DSPE-PEG2000), a formulation which con-
stitutes the basis of the anti-cancer agent Doxils (Fig. S1A and B,
ESI†). Liposomes were employed in this study due to their
extensive protein corona characterisation, their use in nucleic
acid-based biotechnology applications and more recently due
to their promise as a proteomic enrichment tool.10,38,39,45 Our
previous ex vivo and in vivo investigations on protein corona
revealed that even though PEGylation reduces protein adsorption,
it does not completely eliminate binding. PEGylated liposomes
were found to reproducibly interact with low molecular weight
(MW) plasma proteins of low abundance.9–12,15
In order to assess the potential interaction of cfDNA with
PEGylated liposomal surfaces, plasma-incubated liposomes
were purified by size exclusion chromatography (SEC), shown
in Fig. 1A, as described previously.15 Plasma control samples
(without prior incubation with liposomes) were subjected to
the exact same purification process. SEC column-eluted cfDNA
was extracted from chromatographic fractions 1–15, using a
QIAamps circulating nucleic acid extraction kit (QIAGEN) and
subsequently quantified using robust and highly sensitive
LINE-1 real-time qPCR assay (Fig. 2A). Stewart assay was also
performed in order to quantify the amount of liposomes eluted.
As illustrated in Fig. 2A and in agreement with our previous
studies,15 corona-coated liposomes were eluted in chromato-
graphic fractions 5 and 6, while no detectable lipid content was
found in the fractionated plasma control. Distribution of cfDNA
across chromatographic fractions 1–15 revealed significant
differences between plasma-incubated liposomes and the
matched plasma control. In the case of the plasma-incubated
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chromatographic fraction 5, which also contained the largest
population of liposome NPs (66.7%), while liposome-free frac-
tions 7–15 contained relatively small quantities of cfDNA
(o6%). In contrast, a normal distribution of cfDNA was evident
in the fractionated plasma control, with the highest amount of
cfDNA detected in fraction 10 (18.8%). Notably, in the absence
of NPs, only 2.6% of the cfDNA content was detected in
fraction 5. The striking difference in cfDNA distribution
between corona-coated liposomes and the fractionated plasma
control suggests that a significant proportion of cfDNA eluted
in fraction 5 could be associated with the eluted liposomes.
Quantitative detection of cfDNA in the liposome corona
To further purify corona-coated liposomes from any remaining
protein complexes and/or unbound cfDNA, chromatographic
fractions 5 and 6 were pooled, concentrated and subsequently
washed three times using a membrane ultrafiltration column
(Vivaspins, 1 million MWCO). This protocol has been previously
developed by us and also used successfully by others to purify
corona-coated NPs from unbound plasma proteins.9,10,13
To determine the total cfDNA content of the liposomal
corona two different real-time qPCR assays were utilised, as
outlined in Fig. 1B. A real-time qPCR approach was chosen as
the concentration of cfDNA in blood commonly falls below the
lower limit of detection for absorbance and fluorescence-based
DNA quantification methods. Initially, a standardised TaqMans
RNase P detection real-time qPCR assay (Applied Biosystemss) was
used to quantify the cfDNA content of the biomolecule corona in
healthy plasma samples. As illustrated in Fig. 2B, the concentration
of cfDNA measured in the corona samples was significantly higher
in comparison to plasma control samples that underwent the full
purification process (adjusted p-value o 0.0001). A small amount of
cfDNA was identified in purified plasma controls, suggesting a
co-elution of a small population of cfDNA molecules complexed
with large proteins or within extracellular vesicles (Fig. 2B). These
data suggested that most of the cfDNA quantified in corona
samples is associated (directly or indirectly) with the surface of
liposomes and was not passively co-eluted in a size-dependent
manner.
In order to investigate whether the presence of proteins and/
or other molecules in the biomolecule corona affects the direct
quantification of cfDNA, we compared the amount of cfDNA
with and without prior extraction (QIAGEN’s QIAamps circu-
lating nucleic acid extraction kit). Comparable amounts of
cfDNA were detected using the TaqMans RNase P assay both
in corona-coated liposome samples and in cfDNA subsequently
purified from the same corona samples (Fig. 2B). These data
indicated that the real-time qPCR assay was not significantly
inhibited by other molecules present in the corona, allowing
direct cfDNA measurements in the presence of lipid-based NPs
and complex biofluid contaminants. To further investigate
qPCR inhibition in NP-corona samples, a 2-fold dilution was
performed prior to real-time qPCR quantification (Fig. S2A and
B, ESI†). The cfDNA quantity of the 1 : 2 diluted corona sample
was approximately half that of the original measurement (48%),
providing further evidence to support the lack of RNase P qPCR
inhibition in these direct real-time PCR measurements. The
concentration of cfDNA in the NP-corona samples and plasma
controls (with no NPs) was confirmed with a robust and
sensitive LINE-1 qPCR assay (Fig. 2C). Both assays produced
similar values, with RNase P and LINE-1 quantification
methods consistently detecting significantly more cfDNA in
corona samples when compared to plasma controls, as shown
in Fig. 2C.
In terms of reproducibility, the percentage of cfDNA recov-
ered with liposomal NPs was consistent across healthy plasma
and liposome batches (Fig. S3A, ESI†). In addition, plasma
linearity experiments revealed a significant reduction in total
cfDNA content when plasma input volume was lowered, while
the plasma : NP ratio was maintained (adjusted p-values o
0.01 for both 410 mL & 205 mL of plasma when compared to
810 mL) (Fig. S3B, ESI†). In contrast to the linear relationship
observed between plasma volume and cfDNA concentration,
altering the concentration of liposome NPs did not signifi-
cantly affect the amount cfDNA recovered (Fig. S2C, ESI†).
Combined, these data suggested that at the NP concentrations
investigated, liposomes interacted reproducibly with a sub-
population of plasma cfDNA molecules and that a NP : plasma
[mL : mL] ratio of 0.2 was found optimal to recover this fraction
of cfDNA.
Fig. 1 Schematic representation of sample processing and cfDNA quantifi-
cation method pipelines. (A) Schematic overview of human plasma and
liposomal nanoparticle (NP) incubation and subsequent size-exclusion
purification methodology. (B) Method analysis pipeline for plasma processing
(including cfDNA purification) and subsequent q-PCR quantification of
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Detection of cfDNA in ovarian carcinoma liposomal corona
samples
To establish whether cfDNA could also be detected on the
surface of liposomes incubated ex vivo with plasma obtained
from cancer patients, corona-coated liposomes were prepared
upon incubation and purification from plasma samples
obtained from 43 patients with ovarian cancer (18 patients
with FIGO stage I, 8 with stage II, 12 with stage III and 5 with
stage IV) (Table S1, ESI†). Patients with ovarian cancer classi-
fied across all stages of the disease were included in the study
to determine whether cfDNA could be detected in NP corona
samples both at early stages and as the disease progressed.
These samples were quantified directly using a robust high
sensitivity LINE-1 qPCR assay and compared to corona samples
from 11 healthy aged matched females (Fig. 3). When normal-
ised to post-purification liposome concentration, cfDNA was
significantly higher in ovarian cancer samples (all stages, early
stage (I and II) and late-stage (III and IV)) compared to healthy
controls (p values = o0.001, o0.01 and o0.0001, respectively)
(Fig. 3). In addition, average cfDNA content increased from
early (FIGO stage I and II) to late stage (FIGO stage III and IV),
although this was not statistically significant (Fig. 3B). These
data are consistent with previous studies that have proposed
quantification cfDNA as a diagnostic and prognostic biomarker
Fig. 2 Characterisation of cfDNA content in the healthy ex vivo biomolecule corona. (A) cfDNA and liposomal lipid quantification across 15
chromatographic fractions. The purified cfDNA from a single healthy pooled plasma sample incubated with and without liposomal nanoparticles
(NPs) was quantified by a highly-sensitive LINE-1 real-time PCR assay. NPs and cfDNA are expressed as percentage (%) of total recovered across
chromatographic fractions. (B) RNase P real-time cfDNA quantification of pooled ex vivo NP(+) corona samples and NP() controls (size-purified plasma).
cfDNA was measured directly and in samples with additional cfDNA purification step. (C) cfDNA concentrations in NP(+) corona samples and
NP() controls were confirmed using the LINE-1 real-time PCR assay. For graphs B and C cfDNA is expressed as percentage recovery (%) relative to
QIAGEN’s QIAamps Circulating Nucleic Acid extraction kit (average of three replicates). All error bars represent mean and standard deviation. Groups
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for ovarian cancer, with increased cfDNA levels detected with
disease progression.46,47
To determine whether direct cfDNA quantification in ovarian
cancer corona samples would be inaccurate and skewed, with
real-time qPCR inhibition increasing disproportionately with
cancer stage, we compared cfDNA concentration in purified
and unpurified samples for eight late-stage (stage III n = 6,
stage IV n = 2) high-grade serous ovarian cancer samples
(details provided in Fig. S2E, ESI†). Similar cfDNA concentra-
tions were measured for both unpurified ovarian cancer corona
samples and their respective purified cfDNA samples (Fig. S2C,
ESI†). This suggests that real-time qPCR was not significantly
inhibited in these biomolecule corona qPCR reactions and that
no significant cfDNA loss occurred during cfDNA extraction
using QIAGEN’s QIAamps circulating nucleic acid extraction
kit. We were also able to measure the cfDNA content directly in
ovarian cancer plasma samples (diluted 1 : 40), which again
showed no significant difference from the respective purified
plasma cfDNA samples (Fig. S2D, ESI†).
Mass spectrometry (LC-MS/MS) proteomic analysis was then
performed on the 43 samples from ovarian cancer patients and
the 11 samples from healthy controls to investigate whether
proteins known to associate with cfDNA could be detected in
the biomolecule corona (Fig. S4, ESI†). Histone proteins, H2A,
H2B and H4, which are found within the core nucleosome
complex, were detected in the biomolecule corona and were
identified at significantly higher levels in ovarian cancer samples
relative to healthy controls (Fig. S4A, ESI†). Two additional
nucleosome-interacting proteins were identified in these samples,
namely histone-lysine N-methyltransferase 2D and histone
PARylation factor 1 (Fig. S4B, ESI†)48 Combined, these data
confirmed the presence of cfDNA in the biomolecule corona of
liposomes and suggested an indirect interaction which is poten-
tially mediated via the nucleosome complex.
Discussion
Understanding the composition of the biomolecule corona,
spontaneously adsorbed onto the surface of nanoparticles
(NPs), remains challenging due to the diverse physiochemical
characteristics of NPs, as well as the complex multi-molecular
composition of biological fluids.1 To date, the focus has been to
elucidate the blood protein corona composition of various NPs
with different surface chemistry and physiochemical properties.49
However, limited attention has been placed in profiling other bio-
molecules present in the NP corona. Recent studies have high-
lighted the interaction of NPs with lipids and metabolites,21–23
yet the contribution of blood-circulating cell-free DNA (cfDNA)
to the formation of the NP corona remains almost completely
unexplored.
Fragmented cell-free DNA can be actively secreted into the
bloodstream and is also passively released into circulation
during cell death (i.e. apoptosis, necrosis).50 In healthy indivi-
duals, cfDNA levels are usually extremely low, with elevated
concentrations of cfDNA commonly triggered by pathological
Fig. 3 Cell-free DNA (cfDNA) detection in the ex vivo ovarian cancer biomolecule corona. (A) Normalised cfDNA concentration (ng mM1 lipid) in
corona-coated liposomes (ovarian cancer samples and age- and sex-matched healthy controls), measured using a highly-sensitive LINE-1 real-time PCR
assay and robust inhibitor-resistant polyermase. (B) The same data with ovarian cancer patients separated into early stage (1 & 2) and late-stage (3 & 4)
cancers. All error bars represent mean and standard deviation. Three groups or more were compared using a one-way analyses of variance (ANOVA) test
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disease states, such a tumorigenesis, inflammation, ischemia,
trauma and sepsis.50 Cell-free DNA is widely protected from
nuclease digestion by its complexation with a core of histone
proteins, known as nucleosomes.51 Genomic analysis of the
nucleic acid content in blood is of growing interest for diag-
nostic and disease monitoring applications, particularly in the
context of liquid biopsies for cancer.52
Despite recent advances in analysing the blood-circulating
genome, very little attention has been placed on the utilisation
of the spontaneous interaction of NPs with nucleic acids upon
incubation with biological fluids. Recently, Qian and colleagues
investigated the interaction of negatively-charged, carboxylated
magnetic NPs with miRNAs in rat urine samples and suggested
an RNA-induced silencing complex (RISC)-mediated adsorption
of miRNA.33 In a different study, Yun et al. developed a planar-
substrate based protocol in order to investigate the interaction
of metal–phenolic network (MPN)-based nanomaterials with
multiple biomolecules including synthetic single stranded 40 bp
DNA fragments.31 It is important to note however, that these DNA
molecules do not reflect the size and structure of endogenous
plasma cfDNA, nor the molecular complexity of blood.31
Despite the above-mentioned preliminary indications of the
interaction of nucleic acids with the surface of NPs, no studies
have demonstrated the presence of cfDNA in the biomolecule
corona formed when NPs come into contact with human
plasma. The present study aimed to answer this fundamental
question and establish whether cfDNA participates in the
formation of the biomolecule corona in a non-specific, untargeted
manner. In order to investigate this, we used a real-time qPCR-
based approach to quantify cfDNA in the biomolecule corona of
lipid-based NPs upon incubation with human plasma. The NP
corona samples underwent a two-step purification process prior to
cfDNA quantification (with and without an additional cfDNA
purification procedure). Our data provide the first experimental
evidence of the presence of cfDNA in the NP corona samples and
show that the majority of cfDNA detected is associated with
the surface of liposomes and is not passively co-eluted during
purification (Fig. 2A–C). Direct quantification of cfDNA was
possible within complex lipid-based biomolecule corona samples
without prior cfDNA extraction using the QIAamp circulating
nucleic acid extraction kit (QIAGEN). In addition, cfDNA was
successfully purified from lipid NPs using a standard cfDNA
extraction kit, highlighting the compatibility of lipid-based NPs
with downstream purification and quantification methods.
Consistent cfDNA recovery across NP batches (Fig. S3A, ESI†)
suggested its reproducible and stable interaction with the
liposomal surface as part of the biomolecule corona.
The PEGylated liposomes used in this study have a negative
surface charge (Fig. S1A, ESI†), therefore it was considered
unlikely that DNA molecules would be bound directly onto
the liposome surface via electrostatic interactions. Considering
that cfDNA is protected within nucleosome complexes in the
blood,51 we hypothesised that cfDNA may not be directly bound
onto the liposome surface, but through the adsorption of
DNA–protein complexes (illustrated in Fig. 4). This indirect
mechanism of adsorption was further supported by the identifi-
cation of positively charged nucleosome core proteins, including
histone proteins H2A, H2B and H4, in the biomolecule corona by
LC-MS/MS analysis (Fig. S4, ESI†). Our group has previously
detected histone proteins in human and mouse liposomal corona,
both ex vivo and in vivo.9,11,12 Moreover, human histone proteins
(H2B and H4) have also been found to interact with colloidal gold
NPs upon incubation with human plasma.54 Finally, De Paoli and
colleagues demonstrated that calf thymus histone H1 can bind
onto carboxylated-multiwalled carbon nanotubes.55
Our data demonstrated that the corona-containing cfDNA
levels were significantly higher in the biomolecule coronas
formed upon incubation with plasma samples obtained from
ovarian cancer patients (both early- and late-stages) in compar-
ison to healthy controls (Fig. 3). It has been widely reported that
the total amount of cfDNA increases with disease progression
in many different cancer types, such as colorectal, glio-
blastoma, colorectal and breast cancer.47,56–59 It is important
to clarify that circulating DNA originating from the tumour
(ctDNA) commonly accounts for only a small proportion of the
total cfDNA, with the majority of DNA molecules released from
non-malignant cells.51,60 Moreover, cfDNA detected in indivi-
duals with cancer is commonly of heamatopoietic origin and
can be attributed to increased white blood cell turnover and
chemotherapeutic- and/or radiation-induced cell death.51,56
Overall our data here demonstrated that the total amount of
corona cfDNA increases in the presence of ovarian cancer,
Fig. 4 Schematic representation of the formation of a biomolecule corona and the protein-mediated interaction of cell-free DNA (cfDNA) with the
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which renders the need for further studies to estimate the
fraction of ctDNA by analysing tumour-specific mutations. This
approach could offer significant advantages over current cfDNA
purification methods, which lack the sensitivity required to
detect ctDNA in small volumes of human plasma in patients
with low tumour burden, especially pertinent to the challenge
of early cancer detection.
Previous observations have shown that the composition
of the biomolecule corona is directly affected by the presence
of a disease.9 Comprehensive comparison of ‘healthy’ and
‘diseased’ protein coronas has been proposed for the discovery
of diagnostic biomarkers.9–12 For example, we have previously
shown that protein corona quantitatively and qualitatively
changed in the presence of tumorigenesis, with higher total
amount of protein found to interact with intravenously
injected liposomes recovered from melanoma and lung adeno-
carcinoma tumour-bearing mice in comparison to healthy
controls.9 Further analysis revealed that histone H2A was
significantly upregulated in the in vivo lung adenocarcinoma
corona samples.9 Therefore, the increased amount of nucleosome-
related proteins identified in ovarian cancer patients in this
study is likely to extend to other cancer types and NP classes,
as a general reflection of increased histone levels commonly
seen in cancer.61–64
In recent years, other cell-free nucleic acids, such as miRNAs,
have received growing interest as disease biomarkers65 and
although extensive characterisation of the NP corona total nucleic
acid content was beyond the scope of this study, it remains
an important avenue of future research. Blood-circulating RNA
molecules are commonly complexed with proteins, including
those forming the RNA-induced silencing complex (RISC).66 The
potential protein-mediated interaction of RNA with plasma-
incubated NPs remains to be explored, but if confirmed would
add another layer of complexity to the NP biomolecule corona.
In addition, epigenetic analysis of ctDNA, such as differential
methylation profiles can also provide cancer-specific signatures.67
Intriguingly, methylated tumour DNA isolated from the plasma of
cancer patients has been shown to display a strong affinity to gold
nanoparticles and forms the basis of a ctDNA detection tool.68,69
The molecular complexes of cell-free nucleic acids contained
within the biomolecule corona need to be fully elucidated in
order to establish the scope for a sensitive blood-based biomarker
enrichment tool.
The molecular information contained within the NP corona
is far richer than originally described and has been shown to
contain a diverse array of biomolecules including proteins,
lipids, metabolites and now cfDNA. This complex coating on
the surface of NPs has the potential to be able to enhance nano-
drug delivery and NP uptake, but perhaps most significantly,
offers the potential to provide greater sensitivity for liquid
biopsies. Further studies are required to determine whether
tumour-derived nucleic acids (ctDNA, miRNAs, RNAs) are
detectable in the biomolecule corona and whether NPs can
enrich the tumour-specific content obtained from human
blood. Additional studies are also necessary to determine
how the physiochemical properties of different nanomaterials
affect their interaction with nucleic acids. Understanding the
complexity of the biomolecular shell coating the surface NPs
is fundamental in developing new and effective biomedical
applications. Only now, is the diagnostic and therapeutic
potential of the NP corona finally being realised, entering the
nanomedicine field into an exciting new era.
Conclusion
This study has shown that cell-free DNA is present in the
biomolecule corona that forms around lipid-based NPs, upon
incubation with human plasma. The cfDNA content of the
biomolecule corona could be directly quantified in the presence
other biomolecules (e.g. proteins) using conventional real-time
qPCR assays. Furthermore, proteomic analysis of the biomole-
cule corona by LC-MS/MS revealed the presence of nucleosome
complex proteins, suggesting an indirect protein-mediated
interaction of cfDNA with NPs. Notably, the amount of cfDNA
was found to be significantly higher in the coronas formed in
early- and late-stage cancer patient plasma samples compared
to healthy controls, indicating a disease-specific biomolecule
corona formation. This work is thought to pave the way for
future studies, to further understand the mechanism, type and
multi-molecular complex formation and adsorption of blood-
circulating nucleic acids onto the surface of NPs. Equally, our
study highlights the potential exploitation of the biomolecule
corona as a novel blood-analysis nanoscale tool.
Experimental
Plasma samples
Healthy human female pooled K2EDTA plasma samples were
purchased from BioIVT (West Sussex, UK) (Lot #HMN2528).
All ovarian cancer K2EDTA plasma samples were collected
by the MCRC Biobank (details provided in Table S1 and
Fig. S2E, ESI†). Individual age- and sex-matched K2EDTA
plasma controls (female, 45–85 years old) were purchased from
BioIVT (West Sussex, UK) (Table S1, ESI†). All plasma samples
were stored at 80 1C.
Liposome preparation
HSPC : Chol : DSPE-PEG2000 (56.3 : 38.2 : 5.5) liposomes (Doxils
formulation) liposomes were prepared using the thin lipid film
method followed by extrusion as described previously.15 All
liposome batches were diluted to 12.5 mM, with the same batch
of liposomes used for group comparisons. The physiochemical
characteristics of the liposome batches are shown in Fig. S1
(ESI†).
Dynamic light scattering (DLS) for size and zeta-potential
measurements
Liposome size and surface charge were measured as described
previously.15 Liposomes were diluted in distilled water and
measured in size or capillary cuvettes using the Zetasizer Nano
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Biomolecule corona formation (liposome plasma incubation
and purification)
Liposome and plasma incubations and purifications were
performed as described previously.15 In brief, 820 mL human
plasma and 180 mL PEGylated liposomes were incubated for
10 min at 37 1C, shaking at 250 rpm. Unbound proteins and
other unknown biomolecules were removed by size exclusion
chromatography (SEC) (Sepharose CL-4B columns (Sigma-
Aldrich)) followed by membrane ultrafiltration (Vivaspins
columns (Sartorious, Fisher Scientific)). Samples were concen-
trated to 100 mL for characterisation or downstream processing.
For characterisation of individual chromatographic fractions,
samples were concentrated to 100 mL using 1 000 000 molecular
weight cut off (MWCO) Vivaspins membrane ultrafiltration
columns (Sartorious, Fisher Scientific). Plasma controls were
subjected to the same purification process for comparison.
Circulating cell-free nucleic acid extraction
Cell-free nucleic acids were purified from ex vivo plasma
samples, liposomal corona samples and plasma control samples
using a QIAamps Circulating Nucleic Acid Extraction kit and
QIAvac 24 Plus vacuum manifold according to manufacturer’s
instructions (QIAGEN, Hilden, Germany). After an initial sample
lysis step, cell-free nucleic acids were bound onto a silica-based
purification column (QIAGEN mini column). Multiple washing
steps were performed prior to elution of cell-free nucleic acids in
buffer AVE (QIAGEN). All samples were eluted in a final volume
of 50 mL.
Cell-free DNA quantification
Cell-free DNA was measured using two real-time quantitative
PCR (qPCR) assays. The single-copy RNase P probe real-time
assay was performed using TaqMans RNase P Detection
Reagents kit (Life Technologies) and SensiFAST Probe Hi-ROX
master mix (Bioline, Meridian Bioscience). All real-time qPCR
reactions included 7.5 mL of 2 SensiFAST probe mastermix,
0.75 mL 20 RNase P primer/probe mix, 1.75 mL nuclease-free
water (Ambion, Texas, USA) and 5 mL of sample. Cycling
conditions included (95 1C, 5 min)  1, (95 1C, 10 s; 60 1C,
50 s)  40 and were performed on a LightCyclers 96 (Roche,
Basel, Switzerland).
The multi-locus LINE-1 real-time qPCR assay was performed
using primers described previously70 purchased from Inte-
grated DNA Technologies (desalted, 25 nmol scale) using a
robust Terra qPCR Direct SYBR Premix master mix (Takara Bio,
USA). All real-time PCR reactions included 7.5 mL of 2 Terra
qPCR Direct SYBR Premix master mix, 0.75 mL of each 10 mM
(forward and reverse primers), 5.75 mL nuclease-free water
(Ambion, Texas, USA) and 1 mL of sample. Cycling conditions
included (98 1C, 2 min)  1, (98 1C, 10 s; 60 1C, 15 s; 68 1C, 30 s)
 35 and were performed on a LightCyclers 96 (Roche, Basel,
Switzerland).
Sample input was either corona-coated liposomes, puri-
fied cfDNA or plasma samples diluted 1 : 40. Plasma samples
were only quantified using the LINE-1 real-time PCR assay in
combination with the robust Terra qPCR Direct SYBR Premix
master mix.
Mass spectrometry
In-gel digestion of corona proteins was performed prior to
LC-MS/MS analysis, as described previously.15 Digested proteins
were analysed by LC-MS/MS using an UltiMate 3000 Rapid
Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) plus Q
Exactive Hybrid Quadrupole-Orbitrap (Thermo Fisher Scientific,
Waltham, MA, USA) mass spectrometer system. Data were
analysed using Mascot (Matrix Science UK) in combination with
the SwissProt_2016_04 database (taxonomy human). Progenisis
QI software (version 4.3.2, Proteome Software Inc.) was used for
relative protein quantification based on spectral counting and
statistical analyses (one-way analyses of variance (ANOVA)).
Statistical analysis
Statistical comparisons of these data were performed using
GraphPad Prism v.8.2.0. For comparisons of three groups or
more, one-way ANOVA tests were performed followed by the
Tukey’s multiple comparison test (adjusted p values o 0.05
were considered significant). For comparisons of two groups
unpaired Student t-tests were performed (FDR-adjusted
p values o 0.05 were considered significant). All data averages
were presented as mean  standard deviation (SD).
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